^
Association details:
| Biomarker: | BRAF fusion |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Cotellic (cobimetinib) (MEK1 inhibitor) + belvarafenib (RG6185) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
661MO - Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation
Published date:
10/16/2023
Excerpt:
The confirmed objective response rate (ORR), assessed by investigators’ assessment, for SC-A was 60.0%, median progression-free survival (mPFS) was 13.7 months, and median duration of response was 12.0 months (95% CI: 7.43 to 22.34) with median follow-up time 12.9 months, while patients in SC-B showed best response of stable disease...The combination of Belva with Cobi showed promising anti-tumor activity as well as durable responses in patients with BRAF fusions.
Trial ID:
